Inhibitors of PI3K, SYK and BTK pathways are a large focus for pharmaceutical companies with several small molecule inhibitors currently at different stages of development. Enzymatic assays measuring the direct activity of compounds are limited because they do not provide information about the entire pathway controlled by these kinases. If you are interested in learning
Continue Reading
- Products & Solutions
- FDA CLEARED
- About Us
- News & Events
- Contact BDC
- ADDITIONAL SITES